Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729]
Titel:
Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729]
Auteur:
Swords, Ronan T. Greenberg, Peter L. Wei, Andrew H. Durrant, Simon Advani, Anjali S. Hertzberg, Mark S. Lewis, Ian D. Rivera, Gabriel Gratzinger, Dita Fan, Alice C. Felsher, Dean W. Cortes, Jorge E. Watts, Justin M. Yarranton, Geoff T. Walling, Jackie M. Lancet, Jeffrey E.